Management of AIDS-Defining Cancers

  • Authors: David Aboulafia, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/9/18 (What's New)

Summary

  • Patients may present with minimal disease or with rapidly progressive KS, which is associated with substantial morbidity and mortality[Dezube 2000]
  • KS exacerbation can result from IRIS following ART initiation, after corticosteroid use, or with rituximab therapy[Leidner 2005; Pantanowitz 2008]
  • Risk factors for KS-IRIS include HIV-1 RNA > 105 copies/mL, detectable plasma HHV-8 DNA, ART as initial KS treatment, and stage T1 KS[Letang 2013]

Action required

Keywords: Cancer, IRIS

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.